- Home
- HCM
HCM
HUTCHMED (China) Limited
as 07-26-2024 4:00pm EST
Upcoming Earnings Alert:
Get ready for potential market movements as HUTCHMED (China) Limited HCM prepares to release earnings report on 31 Jul 2024.
| Founded: | N/A | Country: | Hong Kong |
| Employees: | N/A | City: | N/A |
| Market Cap: | 3.1B | IPO Year: | N/A |
| Target Price: | $29.70 | AVG Volume (30 days): | 184.3K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.93 - $21.92 | Next Earning Date: | 07-31-2024 |
| Revenue: | $837,999,000 | Revenue Growth: | 135.31% |
| Revenue Growth (this year): | -16.17% | Revenue Growth (next year): | 23.15% |
Latest HUTCHMED (China) Limited News
HCM Breaking Stock News: Dive into HCM Ticker-Specific Updates for Smart Investing
GlobeNewswire
23 days ago
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
GlobeNewswire
a month ago
HUTCHMED to Announce 2024 Half-Year Financial Results
GlobeNewswire
a month ago
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
GlobeNewswire
a month ago
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
GlobeNewswire
a month ago
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
GlobeNewswire
2 months ago
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
GlobeNewswire
2 months ago
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
GlobeNewswire
2 months ago
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
Compare HCM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HCM HUTCHMED (China) Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.